| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8799161 | The Journal of Arthroplasty | 2018 | 17 Pages |
Abstract
TXA, when compared with no pharmacologic hemostatic agent and with EACA, is the most cost-effective strategy to minimize intraoperative blood loss in hip and knee total joint arthroplasties. These findings are robust to sensitivity analyses using clinically plausible probabilities.
Related Topics
Health Sciences
Medicine and Dentistry
Orthopedics, Sports Medicine and Rehabilitation
Authors
Dipak B. MD, Niveditta MPH, Stephanie J. PhD, Wayne E. MD, MS,